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Abstract
Background: The purpose of this study was to examine the relationship between the Medical Outcomes Study-
HIV Health Survey (MOS-HIV) and the SF-12v2 to determine if the latter is adequate to assess the health-related
quality of life (HRQoL) of men and women living with HIV/AIDS. 112 men and women living with HIV/AIDS who
access care at a tertiary HIV clinic in Hamilton, Ontario were included in this cross-sectional analysis. Correlation
coefficients of the MOS-HIV physical and mental health summary scores (PHS and MHS) and the SF-12v2 physical
and mental component summary scales (PCS and MCS) were calculated along with common sub-domains of the
measures including physical functioning (PF), bodily pain (BP), general health perceptions (GH), vitality (VT), social
functioning (SF) and mental health (MH) to explore the relationship between these two HRQoL measures. The sub-
domains role physical (RP) and role emotional (RE) of the SF-12v2 were compared separately to the sub-domain
role functioning (RF) of the MOS-HIV. Weighted kappa scores were calculated to determine agreement beyond
chance between the MOS-HIV and SF-12v2 in assigning a HRQoL state (i.e. low, moderate, good, very good).
Results: The MOS-HIV had mean PHS and MHS summary scores of 47.3 (SD = 11.5) and 49.2 (SD = 10.7) respectively.
The mean SF-12v2 PCS and MCS scores were 47.7 (SD = 11.0) and 44.0 (SD = 10.4). The MOS-HIV and SF-12v2
physical and mental health summary scores were positively correlated (r = 0.84, p < 0.001 and r = 0.76, p < 0.001). All
common sub-domains were significantly correlated at p values from < 0.001 to 0.034. Substantial agreement was
observed in assigning a HRQoL state (Physical:  = 0.788, SE = 0.095; Mental:  = 0.707, SE = 0.095).
Conclusions: This analysis validates the SF-12v2 for measuring HRQoL in adult men and women living with HIV/AIDS.
Background
Health-related quality of life (HRQoL) measures a per-
son’s health status taking into account multiple dimen-
sions including physical or functional, psychological and
social well-being and often relies on patient self-report.
Patrick and Erickson broadly define HRQoL as the
“value assigned to the duration of life as modified by the
impairments, functional states, perceptions, and social
opportunities that are influenced by disease, injury,
treatment, or policy [1].”
A paradigm shift has occurred with HIV now being
considered a chronic illness due to the advancement
and availability of treatment and care. Introduction of
highly active anti-retroviral therapy (HAART) has
resulted in a significant decrease in HIV-related morbid-
ity and mortality across the globe; however, people
living with HIV/AIDS (PHAs) continue to face a variety
of health-related challenges, which can affect many
aspects of their quality of life. As a result, there has
been increasing interest in understanding HRQoL in the
context of HIV infection across a broad spectrum of
HIV research including clinical trials, observational stu-
dies and community-based research. It is important,
however, to ensure that the tools used to measure
HRQoL are in tune with the current state of the HIV
epidemic and reflect the experience of PHAs in their
local and geographical context, while minimizing the
burden placed on those who participate in research
studies.
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are used in HIV research today and there is no consen-
sus on which measures are best, especially considering
that many of these measures were developed in the pre-
HAART era [2]. In a comparative review by Clayson
et al., the SF-36 was identified as the generic measure
with the greatest evidence supporting its use in HIV/
AIDS research [2]. The Medical Outcomes Study HIV
Health Survey (MOS-HIV) was identified as one of the
preferred HIV-specific measures since it is brief and
practical to administer, the input of PHAs was used in
its development, there is well-established evidence for
its reliability, validity and responsiveness and it has been
successfully used in clinical trials [2]. Shahriar et al.
countered Clayson’s review stating that there was insuf-
ficient evidence to recommend the use of the MOS-HIV
over the SF-36 and that more head-to-head comparisons
were needed [3].
The MOS-HIV is a 35-item questionnaire that includes
eleven dimensions of HRQoL including general health
perceptions (GHP), bodily pain (BP), physical functioning
(PF), role functioning (RF), social functioning (SF), men-
tal health (MH), energy/vitality (EV), cognitive function-
ing (CF), health distress (HD), overall quality of life (QL)
and health transition (HT) allowing for the generation of
physical (PHS) and mental (MHS) health summary
scores. Development of the MOS-HIV began in 1987 and
items selected from the SF-20 were the foundation for its
construction [3-5]. The MOS-HIV was developed to pro-
vide a brief, comprehensive measure of functional status
and well-being of PHAs enrolled in large-scale clinical
trials and has been shown to be internally consistent and
responsive to a number of outcomes including infections,
adverse events, increased symptoms and AIDS-related
events [2,4,5]. The MOS-HIV has also been used in stu-
dies with a variety of patient groups including treatment-
naïve, asymptomatic PHAs to those with more advanced
HIV and opportunistic infections. MOS-HIV items are
rescaled to a number between 0 and 100, with a higher
score reflecting better health and HRQoL [4-6].
The 12-item short-form (SF-12v2) health survey, now
in its second version, was developed out of a strategy to
construct a shorter version of the SF-36 Health Survey
reflecting the same sub-domains including general
health perceptions (GHP), bodily pain (BP), physical
functioning (PF), role physical (RP), role emotional (RE),
social functioning (SF), mental health (MH) and energy/
vitality (EV) [4,7]. The SF-12v2 reproduces more than
90% of the variance of the physical and mental compo-
nent summary scales of the SF-36 in the general US
population, takes significantly less time to complete
than the SF-36, reducing burden on research partici-
pants; and demonstrated high two-week test-retest relia-
bility correlations for both the physical (r = 0.89) and
mental (r = 0.76) health summary scores [6,8]. Han
et al. demonstrated the SF-12v2 to be a reasonable and
effective replacement for the SF-39, a similar measure to
the MOS-HIV, in studies of people living with advanced
H I Vd i s e a s eb yc o m p a r i n gf i v ed o m a i n so ft h eS F - 1 2
(namely physical functioning, general health perceptions,
bodily pain, mental health and energy/fatigue) to the
SF-39 [9]. This analysis demonstrated that the burden of
data requirements for both participants and investigators
as well as redundancy of questions asked could be
reduced by using the SF-12v2 [8].
The purpose of this study was to give further rationale
for using the SF-12v2 in HIV research by examining the
relationship between the MOS-HIV and the SF-12v2 to
determine if, when compared to the HIV-specific MOS-
HIV, the SF-12v2 is an adequate measure to assess the
health-related quality of adult men and women living
with HIV/AIDS.
Methods
The study population consisted of 112 adult men and
women living with HIV/AIDS who accessed care at the
McMaster University Medical Centre Special Immunology
Services outpatient clinic in Hamilton, Ontario and were
enrolled in the Canadian HIV Vascular Study, a multi-cen-
tre, prospective cohort study examining the relationship
between HIV infection, anti-retroviral therapy and cardio-
vascular disease. The Canadian HIV Vascular Study was
approved by the Hamilton Health Sciences/McMaster
University Faculty of Health Sciences Research Ethics
Board; all participants gave their informed consent prior
to their inclusion in this study and analysis of their data.
MOS-HIV and SF-12v2 questionnaires completed on the
same day during the Canadian HIV Vascular Study base-
line interview were used. The MOS-HIV served as the
reference standard as it is the primary HIV-specific
HRQoL measure used in clinical and observational HIV
research; there is no evidence that the SF-39, a similar
HRQoL scale, has ever been used in HIV research. The
continuous PHS and MHS of the MOS-HIV and the PCS
and MCS of the SF-12v2 were assessed for normality. Cor-
relations between baseline physical and mental health
summary scores of both measures were calculated using
SPSS v17; Pearson correlation coefficients were calculated
because of the lack of skew in the distributions of the
summary scores. Pearson correlation coefficients were
used to investigate the relationship between common sub-
domains of the MOS-HIV and SF-12v2 including physical
functioning (PF), bodily pain (BP), general health percep-
tions (GH), energy/vitality (VT), social functioning (SF)
and mental health (MH). The sub-domains role physical
(RP) and role emotional (RE) of the SF-12v2 were com-
pared separately to the domain role functioning (RF) of
the MOS-HIV as these two domains capture the overall
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correlation coefficients and the Multitrait-Multimethod
Matrix method as outlined by Campbell and Fiske [10]
were used to assess convergent and discriminant validity.
Convergent validity indicates the degree to which sub-
domains of the measures are related whereas discriminant
validity indicates to what extent the sub-domains are not
related theoretically; both convergent and discriminant
validity were assessed statistically [11]. A cut-off of r ≥
0.70 was chosen to determine the degree of convergent
validity [12,13]; a cut-off of r < 0.85 was chosen to assess
discriminant validity [11].
We also investigated agreement between the two mea-
sures in assigning individuals to a HRQoL state, for
example, low, moderate, good and very good HRQoL.
Quartile values of the PHS and MHS from the MOS-
HIV generated out of descriptive statistics of the cohort
were used to establish levels of low (PHS: 0-39.09;
MHS: 0-41.03), moderate (PHS: 39.10-48.47; MHS:
41.04-49.89), good (PHS: 48.48-57.34; MHS: 49.90-
58.50) and very good (PHS: 57.35-100; MHS: 58.51-100)
HRQoL. SF-12v2 PCS and MCS quartile values were
calculated for low (PCS: 0-41.02; MCS: 0-36.79), moder-
ate (PCS: 41.03-51.35; MCS: 36.80-44.44), good (PCS:
51.36-56.27; MCS: 44.45-52.69) and very good (PCS:
56.28-100; MCS: 52.70-100) HRQoL and were com-
pared to the MOS-HIV quartiles for each individual
generating a 4 x 4 table. Weighted kappa ()s c o r e sa s
per Fleiss and Cohen [14] were calculated using soft-
ware by Cyr and Francis [15] in order to determine the
chance-corrected agreement between the MOS-HIV and
SF-12v2 in assigning individuals to levels of HRQoL.
Weighted kappa values were interpreted as follows: less
than 0 – poor agreement; 0 to 0.2 – slight agreement;
0.2 to 0.4 – fair agreement; 0.4-0.6 – moderate agree-
ment; 0.6-0.8 – substantial agreement; 0.8-1.0 – almost
perfect agreement [16].
A secondary analysis was conducted using the baseline
clinical and HRQoL data from 96 of the men and
women in the cohort from whom we had complete
baseline data in order to determine the clinical validity
of the SF-12v2 compared to the MOS-HIV. Pearson cor-
relation coefficients were calculated in univariable analy-
sis for all clinical variables of interest with each HRQoL
summary score from both measures. Four linear regres-
sion models were created in SPSSv17 utilizing the physi-
cal health and mental health summary scores of both
the SF-12v2 and MOS-HIV as outcome measures. The
overall fit of each model was assessed and standardized
beta coefficients for each clinical variable of interest
were reviewed for statistical significance and contribu-
tion to the model. The following clinical variables were
included in each regression model: age, gender, years
living with HIV, smoking (current and former), current
marijuana use, drug use (including cocaine and heroin),
c u r r e n tr e c e i p to faN N R T I - b a s e do rP I - b a s e dH A A R T
regimen, nadir CD4 cell count and average number of
hours slept each night. These variables were chosen
because they have shown to affect physical or mental
HRQoL in the literature [17-28].
Results
Table 1 presents baseline characteristics of the 112 men
and women living with HIV/AIDS who were included in
the analysis. The cohort was predominantly male with a
mean age of 49.1 years (SD = 8.2) and Caucasian ethni-
city. The HIV transmission risk factor cited most fre-
quently was sex with other men (61.6%) followed by
heterosexual/bisexual sex (29.5%) and injection drug use
(6.3%). The cohort had a mean CD4 T-lymphocyte
count of 507 cells/ml of blood at their baseline study
visit (SD = 280.3) and had lived with HIV, on average,
for 12.0 years (SD = 7.6). Table 2 presents the descrip-
tive statistics for the physical and mental health sum-
mary scores as well as all domains of the MOS-HIV and
SF-12v2. The mean MOS-HIV physical health summary
score was 47.3 (SD = 11.5) ranging from 22.4 to 63.2
whereas the mean MOS-HIV mental health summary
score was 49.2 (SD = 10.7) ranging from 20.5 to 66.7.
The mean physical and mental component summary
scales of the SF-12v2 were similar at 47.7 (SD = 11.0)
ranging from 16.2 to 63.4 and 44.0 (SD = 10.4) ranging
from 16.7 to 62.4, respectively.
Table 1 Baseline characteristics of participants
N = 112 Mean (SD); Min-Max
Age (years) 49.1 (8.2); 31-75
Number of years living with HIV 12.0 (7.6); 1-52
Baseline CD4 (at study visit) 507.4 (280.3); 50-1170
N (%)
Gender
Male 97 (86.6)
Female 14 (12.5)
Transgendered 1 (0.9)
Currently receiving HAART 87 (77.7)
Ethnicity
Caucasian 100 (89.3)
Black 7 (6.3)
Other 3 (2.7)
First Nation 2 (1.8)
HIV Transmission Risk Factor
MSM 69 (61.6)
Heterosexual/Bisexual 33 (29.5)
IDU 7 (6.3)
Hemophilia 5 (4.5)
Blood Products 3 (2.7)
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comparing the physical and mental health summary
scores of the MOS-HIV and SF-12v2 as well as scores of
all sub-domains in each measure. The MOS-HIV and SF-
12v2 were positively correlated with regard to both the
physical and mental health summary scores respectively
(r = 0.84, p < 0.001 and r = 0.76, p < 0.001). A compari-
son of the MOS-HIV and SF-12v2 common domains
including PF, BP, GH, VT, SF and MH yielded positive
correlations for all categories (PF: r = 0.90; BP: r = 0.82;
G H :r=0 . 8 0 ;V T :r=0 . 7 2 ;S F :r=0 . 6 8 ;M H :r=0 . 5 8 ;a l l
significant at p < 0.001). The domains role physical and
role emotional of the SF-12v2 were compared separately
to the domain role functioning of the MOS-HIV yielding
slightly lower, yet positive correlations (RP: r = 0.69; RE:
r = 0.49; p < 0.001). Tables 4 and 5 present the inter-
domain correlations of the SF-12v2 and MOS-HIV,
respectively. Five of the inter-scale correlations of the SF-
12v2 were low (r range = 0.24-0.39), however, the
remaining correlations were moderately to highly asso-
ciated (r range = 0.40-0.86, all statistically significant at p
values from < 0.001 to 0.012). Inter-scale correlations of
the MOS-HIV were similar with moderate to high inter-
scale correlations ranging from 0.40 to 0.70, all statisti-
cally significant at p < 0.001. The two exceptions were
the associations between the PF and MH (r = 0.36) and
between GH and CF (r = 0.39). Overall, by comparing
the Pearson correlations between the measures as well as
the inter-domain correlations within the SF-12v2 and
MOS-HIV to the cut-off values of r≥0.70 and r < 0.85
chosen, it was demonstrated that both instruments have
good convergent and discriminant validity, respectfully.
The MOS-HIV and SF-12v2 demonstrated substantial
agreement for assigning individuals to specific states of
HRQoL based on their MOS-HIV physical and mental
health summary scores with weighted  scores of 0.788
(SE = 0.095) and 0.707 (SE = 0.095) for agreement of
physical and mental health, respectively.
Lastly, the univariable and multivariable analyses inves-
tigating clinical correlates of HRQoL between the SF-
12v2 and MOS-HIV demonstrated moderate agreement
(Table 6). There was similar directionality and magnitude
of association between the two measures for both the
physical and mental health summary scores. In univari-
able analysis, a history of drug use was associated with a
lower physical health summary score for both the MOS-
HIV [r = - 0.216 (95% CI - 0.399, - 0.017)] and SF-12v2,
however the correlation was not significant for the SF-
12v2 [r = - 0.157 (95% CI - 0.346, 0.044)]. The MOS-HIV
and SF-12v2 mental health summary scores demon-
strated similar trends with regard to male gender [MOS-
HIV: r = 0.222 (95% CI 0.023, 0.404); SF-12v2: r = 0.164
(95% CI - 0.037, 0.352)] and hours slept each night
[MOS-HIV: r = 0.194 (95% CI - 0.006, 0.379); SF-12v2: r
= 0.207 (95% CI 0.007, 0.391)]. In multivariable analysis,
the trend for the MHS was maintained for male gender
(MOS-HIV: b = 0.260, p = 0.013; SF-12v2: b =0 . 1 9 9 ,p=
0.052) and hours slept each night (MOS-HIV: b = 0.283,
p = 0.011; SF-12v2: b = 0.270, p = 0.014). The one discre-
pancy between the two measures was with regard to
Table 2 Mean, Standard Deviation, Median and Min-Max Values for Components/Domains of MOS-HIV and SF-12v2
(n = 112)
MOS-HIV SF-12v2
Component or Domain Mean (SD) Median Min-Max Component or Domain Mean (SD) Median Min-Max
PHS 47.3 (11.5) 48.5 22.4-63.2 PCS 47.7 (11.0) 51.3 16.2-63.4
MHS 49.2 (10.7) 49.9 20.5-66.7 MCS 44.0 (10.4) 44.4 16.7-62.4
GHP 48.9 (10.6) 48.3 28.9-67.6 GHP 45.4 (11.4) 44.7 18.9-62.0
BP 50.8 (9.1) 50.6 27.6-62.2 BP 46.0 (11.9) 47.3 16.7-57.4
PF 47.8 (11.2) 51.2 20.2-58.1 PF 47.3 (11.4) 52.2 22.1-56.5
RF 48.0 (10.8) 56.6 32.0-56.6 RP 46.4 (10.6) 48.0 20.3-57.2
RE 44.6 (12.2) 44.9 11.3-56.1
SF 46.5 (11.6) 47.8 10.2-57.2 SF 43.7 (11.2) 46.5 16.2-56.6
MH 50.7 (11.7) 53.6 17.5-66.3 MH 43.3 (10.0) 46.3 15.8-64.5
EV 47.4 (11.6) 48.9 24.3-68.6 EV 49.3 (9.9) 47.7 27.6-67.9
CF 46.3 (10.9) 48.3 14.1-58.1
HD 51.8 (10.5) 53.7 20.4-62.0
QL 49.2 (9.8) 53.0 27.7-65.6
Abbreviations: PHS - physical health summary score; MHS - mental health summary score; PCS - physical component summary scale; MCS - mental component
summary scale; GHP - general health perceptions; BP - bodily pain; PF - physical functioning; RF - role functioning; RP - role physical; RE - role emotional; SF -
social functioning; MH - mental health; EV - energy/vitality; CF - cognitive functioning; HD - health distress; QL - quality of life.
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In univariable analysis, the mental health summary score
of both measures was not significantly correlated with
being a current smoker [MOS-HIV: r = - 0.011 (95% CI -
0.211, 0.189); SF-12v2: r = 0.044 (95% CI - 0.157, 0.242)]
or former smoker [MOS-HIV: r = - 0.014 (95% CI -0.213,
0.187); SF-12v2: r = 0.048 (95% CI -0.153, 0.246)]. In
multivariable analysis, current smoker and former smo-
ker were significant predictors of the MOS-HIV MHS
(b = 4.226, p = 0.044; b = -4.25, p = 0.043, respectively),
but not of the SF-12v2 MCS (b =1 . 8 6 7 ,p=0 . 3 6 3 ;b =
-1.865, p = 0.364, respectively), even though directionality
of the associations were similar. It should be noted that
only the regression model involving the SF-12v2 MCS as
the dependent variable was statistically significant (F =
1.955, p = 0.044). The other regression models were not
significant: SF-12v2 PCS – F = 0.924, p = 0.522; MOS-
HIV MHS: F = 1.735, p = 0.80; MOS-HIV PHS: F =
1.352, p = 212.
Discussion
This preliminary analysis suggests that the SF-12v2 is an
appropriate measure of health-related quality of life of
men and women living with HIV/AIDS compared to the
MOS-HIV demonstrating high correlation and good
convergent and discriminant validity when compared to
the physical and mental health summary scores of the
MOS-HIV and common sub-domains. Furthermore, the
Table 3 Correlation between SF-12v2 and MOS-HIV (n = 112)
MOS-HIV
PF PN GH VT SF MH RF CF QL HD PHS MHS
SF12v2
PF 0.9 0.68 0.63 0.61 0.41 0.31 0.62 0.41 0.47 0.56 0.84 0.52
BP 0.62 0.82 0.5 0.52 0.43 0.37 0.46 0.36 0.36 0.55 0.7 0.49
GH 0.56 0.52 0.8 0.64 0.43 0.41 0.47 0.2 0.58 0.45 0.66 0.56
VT 0.54 0.48 0.6 0.72 0.39 0.36 0.43 0.36 0.54 0.37 0.62 0.55
SF 0.4 0.46 0.44 0.5 0.68 0.64 0.37 0.4 0.53 0.5 0.52 0.65
MH 0.45 0.49 0.57 0.76 0.53 0.58 0.43 0.52 0.57 0.51 0.59 0.71
RP 0.78 0.67 0.7 0.7 0.53 0.39 0.69 0.38 0.55 0.5 0.85 0.58
RE 0.44 0.49 0.47 0.66 0.55 0.68 0.49 0.63 0.46 0.64 0.56 0.75
PCS 0.85 0.74 0.69 0.57 0.4 0.24* 0.6 0.25 0.46 0.49 0.84 0.44
MCS 0.27* 0.36 0.45 0.69 0.58 0.71 0.36 0.56 0.54 0.52 0.44 0.76
SF12: PF = physical functioning; BP = bodily pain; GH = general health perceptions; VT = vitality; SF = social functioning; MH = mental health; RP = role physical;
RE = role emotional; PCS = physical component summary scale; MCS = mental component summary scale.
MOS-HIV: PF = physical functioning; PN = pain; GH = general health perceptions; VT = energy/fatigue; SF = social functioning; MH = mental health; RF = role
functioning; CF = cognitive function; QL = quality of life; HD = health distress; HT = health transition; PHS = physical health summary; MHS = mental health
summary.
Note: All correlations were statistically significant at p < 0.001 except for *, which were significant at p < 0.05.
Table 4 Inter-domain correlations within SF-12v2 (n = 112)
PF BP GH VT SF MH RP RE PCS MCS
PF 0.66* 0.50* 0.54* 0.37* 0.45* 0.77* 0.39* 0.89* 0.21+
BP 0.47* 0.42* 0.41* 0.44* 0.62* 0.39* 0.80* 0.26+
GH 0.59* 0.40* 0.55* 0.54* 0.33* 0.66* 0.41*
VT 0.24* 0.86* 0.59* 0.45* 0.49* 0.65*
SF 0.40* 0.43* 0.55* 0.35* 0.61*
MH 0.51* 0.59* 0.36* 0.84*
RP 0.54* 0.82* 0.37*
RE 0.25+ 0.83*
PCS 0.08
MCS
SF12: PF = physical functioning; BP = bodily pain; GH = general health perceptions; VT = vitality; SF = social functioning; MH = mental health; RP = role physical;
RE = role emotional; PCS = physical component summary scale; MCS = mental component summary scale.
*: Statistically significant (p < 0.001).
+: Statistically significant (p < 0.05).
Ion et al. AIDS Research and Therapy 2011, 8:5
http://www.aidsrestherapy.com/content/8/1/5
Page 5 of 9SF-12v2 had substantial agreement with the MOS-HIV
in assigning individuals to a specific HRQoL status and
determining clinically relevant correlates of HRQoL.
It is important to point out that this analysis does not
account for the HRQoL domains of cognitive function-
ing, health distress and health transition, which are cap-
tured in the MOS-HIV but are not represented in the
SF-12v2. These domains are used to derive the mental
health summary score of the MOS-HIV, which may
help to explain the weaker correlation between the mea-
sures in the MHS as well as the differences in determin-
ing clinically relevant correlates of HRQoL. If the SF-
12v2 is used as a HRQoL measure in any HIV research
study, it would have to be with the caveat that these
three HRQoL domains were not important outcomes or
were not relevant to the population under study.
It should be noted that the mean physical and mental
health summary scores were lower than the mean score
of 50 for the reference population. This supports the lit-
erature that despite the advancement of HAART and
decline in HIV-related morbidity and mortality, people
living with HIV continue to experience health-related
challenges and generally have lower physical and mental
HRQoL scores when compared to the general popula-
tion. A cross-sectional questionnaire-based study con-
ducted by Miners et al. found that men and women
living with HIV in the United Kingdom scored lower on
all five domains on the EQ-5D quality of life measure
including mobility, self-care, usual activities, pain/dis-
comfort and anxiety/depression irrespective of similari-
ties in age and gender [22]. Univariable and subsequent
multivariable regression analysis demonstrated that peo-
ple living with HIV had significantly lower utility and
visual analogue scale scores on the EQ-5D compared
with the general population; HIV infection indepen-
dently decreased the utility and visual analogue scale
scores of the EQ-5D by 20% [22]. In addition, the mean
mental health summary scores were relatively higher for
people completing the MOS-HIV compared to the SF-
12v2. This may reflect the additional domains captured
in the MOS-HIV (i.e. health distress, health transition,
etc.) that are combined to determine the mental health
summary score or may have arisen due to chance.
The SF-12v2 is currently being used in HIV research
in Canada to better understand the HRQoL of indivi-
duals living with HIV/AIDS including assessing changes
over time, but had not been formally compared to the
MOS-HIV. The Canadian HIV Vascular Study investiga-
tors chose the SF-12v2 over the MOS-HIV in order to
reduce questionnaire burden on participants, and the
SF-12v2 is also being used in the Ontario HIV Treat-
ment Network Cohort Study to understand yearly
changes in HRQoL. The SF-12v2 is a contemporary
HRQoL measurement tool with accessible language and
efficiency in its administration. Ease in reading and
comprehending the SF-12v2 would also result in fewer
errors by the participant.
Although this is not necessarily synonymous with the
level of understanding of the intended meaning of the
items, anecdotally, the authors have experienced mini-
mal issues in interpreting the SF-12v2, but have often
had questions from participants completing the MOS-
HIV, including redefinition of colloquial language such
as “pep,”“ blue” and “down in the dumps.” The MOS-
HIV typically takes much longer to complete than the
SF-12v2. Locally, participants involved in research at the
McMaster University Medical Centre usually need 5
to 10 minutes to complete the MOS-HIV, whereas
Table 5 Inter-domain correlations within MOS-HIV (n = 112)
PF PN GH VT SF MH RF CF QL HD PHS MHS
PF 0.67 0.69 0.67 0.50 0.36 0.64 0.43 0.56 0.58 0.90 0.58
PN 0.61 0.66 0.46 0.47 0.54 0.49 0.47 0.63 0.81 0.61
GH 0.68 0.51 0.47 0.64 0.39 0.62 0.60 0.82 0.68
VT 0.62 0.62 0.57 0.50 0.62 0.61 0.80 0.79
SF 0.70 0.44 0.48 0.58 0.56 0.66 0.76
MH 0.40 0.60 0.50 0.68 0.48 0.89
RF 0.47 0.46 0.55 0.81 0.58
CF 0.41 0.70 0.52 0.77
QL 0.45 0.64 0.71
HD 0.65 0.85
PHS 0.72
MHS
MOS-HIV: PF = physical functioning; PN = pain; GH = general health perceptions; VT = energy/fatigue; SF = social functioning; MH = mental health; RF = role
functioning; CF = cognitive function; QL = quality of life; HD = health distress; HT = health transition; PHS = physical health summary; MHS = mental health
summary.
Note: All p values are < 0.001.
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than 2 minutes and express ease in completing the SF-
12v2 more so than the MOS-HIV. Miscomprehension of
terms used in HRQoL measures by participants can
result in inaccurate measurement of this important con-
struct. It is important to use a HRQoL measure that is
culturally relevant, accessible, quick to administer
and reflects the current experiences of PHAs. It should
be acknowledged that it was not possible to ask
participants directly regarding the ‘burden’ or time
required to complete both the MOS-HIV and SF-12v2.
This would have offered an interesting perspective to
this analysis and the subsequent decision of which mea-
sure to use in HIV research studies. Another considera-
tion when measuring HRQoL is to what extent the
items and dimensions captured in the scale resonate
with participants and accurately depict the current rea-
lity of PHAs. It was not possible to elicit feedback from
Table 6 Correlation coefficients (95% CIs) and multivariable regression (standardized beta coefficients) exploring
correlates of HRQoL
Clinical variable of interest MOS-HIV SF-12v2 MOS-HIV SF-12v2
Physical health
summary score (PHS)
Physical component
summary scale(PCS)
Mental health summary
score (MHS)
Mental component
summary scale(MCS)
r (95% CI) r (95% CI) r (95% CI) r (95% CI)
b (p value) b (p value) b (p value) b (p value)
Age r = -0.011 r = -0.067 r = 0.128 r = 0.228
(-0.211, 0.189) (-0.767, 0.543) (-0.074, 0.320) (0.029, 0.409)
b = -0.063 (p = 0.579) b = -0.116 (p = 0.321) b = 0.153 (p = 0.169) b = 0.215 (p = 0.052)
Male Gender r = 0.155 r = 0.115 r = 0.222 r = 0.164
(-0.046, 0.344) (-0.087, 0.308) (0.023, 0.404) (-0.037, 0.352)
b = 0.174 (p = 0.099) b = 0.102 (p = 0.345) b = 0.260 (p = 0.013) b = 0.199 (p = 0.052)
Years living w HIV r = -0.117 r = -0.166 r = -0.059 r = 0.197
(-0.310, 0.085) (-0.354, 0.035) (-0.143, 0.256) (-0.003, 0.382)
b = -0.163 (p = 0.161) b = -0.213 (p = 0.076) b = -0.016 (p = 0.886) b = 0.130 (p = 0.246)
Current smoker r = -0.113 r = -0.069 r = -0.011 r = 0.044
(-0.306, 0.089) (-0.265, 0.133) (-0.211, 0.189) (-0.157, 0.242)
b = -0.973 (p = 0.646) b = -1.279 (p = 0.556) b = 4.226 (p = 0.044) b = 1.867 (p = 0.363)
Former smoker r = -0.105 r = -0.064 r = -0.014 r = 0.048
(-0.299, 0.097) (-0.261, 0.138) (-0.213, 0.187) (-0.153, 0.246)
b = 0.869 (p = 0.681) b = 1.240 (p = 0.568) b = -4.254 (p = 0.043) b = -1.865 (p = 0.364)
Currently uses marijuana r = -0.099 r = -0.065 r = -0.032 r = -0.045
(-0.293, 0.103) (-0.262, 0.137) (-0.231, 0.169) (-0.243, 0.156)
b = -0.186 (p = 0.098) b = -0.097 (p = 0.397) b = -0.128 (p = 0.244) b = -0.143 (p = 0.187)
Has used drugs (including
cocaine and heroin)
r = -0.216 r = -0.157 r = -0.119 r = -0.103
(-0.399, -0.017) (-0.346, 0.044) (-0.312, 0.083) (-0.297, 0.099)
b = -0.199 (p = 0.081) b = -0.129 (p = 0.266) b = -0.179 (p = 0.109) b = -0.094 (p = 0.392)
Currently receiving PI-based
regimen
r = 0.016 r = -0.027 r = 0.084 r = 0.137
(-0.185, 0.215) (-0.226, 0.174) (-0.118, 0.279) (-0.065, -0.128)
b = 0.067 (p = 0.582) b = 0.025 (p = 0.843) b = 0.117 (p = 0.326) b = 0.157 (p = 0.185)
Currently receiving NNRTI-
based regimen
r = 0.177 r = 0.141 r = 0.125 r = 0.181
(-0.024, 0.364) (-0.061, 0.332) (-0.077, 0.317) (-0.020, 0.368)
b = 0.087 (p = 0.479) b = 0.116 (p = 0.357) b = 0.006 (p = 0.961) b = 0.050 (p = 0.672)
Hours slept each night r = 0.078 r = -0.008 r = 0.194 r = 0.207
(-0.124, 0.274) (-0.208, 0.192) (-0.006, 0.379) (0.007, 0.391)
b = 0.141 (p = 0.209) b = -0.018 (p = 0.877) b = 0.283 (p = 0.011) b = 0.270 (p = 0.014)
Nadir CD4 cell count r = -0.057 r = -0.067 r = -0.093 r = -0.045
(-0.254, 0.154) (-0.263, 0.135) (-0.288, 0.109) (-0.767, -0.543)
b = -0.018 (p = 0.883) b = -0.080 (p = 0.515) b = -0.018 (p = 0.880) b = 0.112 (p = 0.336)
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inclusion of the MOS-HIV and SF-12v2 in this analysis;
this would have offered another interesting perspective
to this comparison.
This analysis may not be generalizable to all PHAs.
The cohort was comprised predominantly of men with
an average age of 48.6 years (ranging from 31 to 75
years) whose major HIV transmission risk factor was
intercourse with other men; the study sample is reflec-
tive of the early HIV epidemic and may not be compar-
able to today’s population of people living with HIV/
AIDS. Eighty-nine per cent were of Caucasian ethnicity
and only 12.6% of the cohort were women, therefore,
caution should be taken when attempting to apply these
results to people from different ethnocultural commu-
nities and gender identities. These findings must also be
considered with caution due to the relatively small sam-
ple size.
Conclusions
This preliminary analysis suggests that the SF-12v2 is an
efficient and practical HRQoL questionnaire taking, on
average, less than two minutes to complete. This
HRQoL measure may enable timely collection of quality
of life data in broader areas of research than in the past
while reducing the redundancy and questionnaire bur-
den placed on participants. Confirmatory studies in lar-
ger and more representative populations are needed.
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